Smart Nanocarriers for Targeted Drug Delivery in treatment of oral cancer

سال انتشار: 1404
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 23

فایل این مقاله در 9 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_JODHN-2-3_006

تاریخ نمایه سازی: 3 مرداد 1404

چکیده مقاله:

Oral cancer remains a significant global health challenge due to its high morbidity, recurrence rate, and resistance to conventional therapies. Traditional treatments such as surgery, chemotherapy, and radiotherapy often cause severe side effects and lack specificity, leading to damage of healthy tissues. In recent years, smart nanocarriers have emerged as a promising strategy for targeted drug delivery in the treatment of oral cancer. These nanoscale systems are engineered to enhance drug solubility, stability, and bioavailability, while ensuring site-specific delivery and controlled release of therapeutic agents. Smart nanocarriers—such as liposomes, polymeric nanoparticles, dendrimers, and stimuli-responsive systems—can be functionalized with ligands that recognize overexpressed receptors on oral cancer cells, allowing precise targeting. Furthermore, they can be designed to respond to internal (pH, redox, enzymes) or external (temperature, magnetic field, light) stimuli, triggering drug release specifically in the tumor microenvironment. This targeted approach minimizes systemic toxicity and improves therapeutic efficacy. This review explores recent advances in the design, functionality, and clinical potential of smart nanocarriers for oral cancer therapy, highlighting their role in personalized and minimally invasive treatment strategies. Oral cancer remains a significant global health challenge due to its high morbidity, recurrence rate, and resistance to conventional therapies. Traditional treatments such as surgery, chemotherapy, and radiotherapy often cause severe side effects and lack specificity, leading to damage of healthy tissues. In recent years, smart nanocarriers have emerged as a promising strategy for targeted drug delivery in the treatment of oral cancer. These nanoscale systems are engineered to enhance drug solubility, stability, and bioavailability, while ensuring site-specific delivery and controlled release of therapeutic agents. Smart nanocarriers—such as liposomes, polymeric nanoparticles, dendrimers, and stimuli-responsive systems—can be functionalized with ligands that recognize overexpressed receptors on oral cancer cells, allowing precise targeting. Furthermore, they can be designed to respond to internal (pH, redox, enzymes) or external (temperature, magnetic field, light) stimuli, triggering drug release specifically in the tumor microenvironment. This targeted approach minimizes systemic toxicity and improves therapeutic efficacy. This review explores recent advances in the design, functionality, and clinical potential of smart nanocarriers for oral cancer therapy, highlighting their role in personalized and minimally invasive treatment strategies.

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • 1. Kabra DP, Roghini DR, Ghosh DS, Karande DS, Chandran ...
  • 2. Chamoli A, Gosavi AS, Shirwadkar UP, Wangdale KV, Behera ...
  • 3. Pouyan A, Ghorbanlo M, Eslami M, Jahanshahi M, Ziaei ...
  • 4. Asadi A, Rezaee M, Ghahramani Y. Biomimetic nanomaterials in ...
  • 5. Yang Z, Sun P, Dahlstrom KR, Gross N, Li ...
  • 6. Debela DT, Muzazu SG, Heraro KD, Ndalama MT, Mesele ...
  • 7. Ahmad A, Imran M, Sharma N. Precision nanotoxicology in ...
  • 8. Ranasinghe R, Mathai ML, Zulli A. Cisplatin for cancer ...
  • 9. Gavas S, Quazi S, Karpiński TM. Nanoparticles for cancer ...
  • 10. Ghahramani Y, Tabibi SS, Khan MMR, Asadi A, Mohammadi ...
  • 11. Mousavi SM, Hashemi SA, Fallahi Nezhad F, Binazadeh M, ...
  • 12. Kenchegowda M, Rahamathulla M, Hani U, Begum MY, Guruswamy ...
  • 13. Mousavi SM, Hashemi SA, Mazraedoost S, Chiang W-H, Yousefi ...
  • 14. Bajracharya R, Song JG, Patil BR, Lee SH, Noh ...
  • 15. Khan MI, Hossain MI, Hossain MK, Rubel M, Hossain ...
  • 16. Moazami F, Gholami A, Mehrabi V, Ghahramani Y. Evaluation ...
  • 17. Rahim MA, Jan N, Khan S, Shah H, Madni ...
  • 18. Adl A, Abbaszadegan A, Gholami A, Parvizi F, Ghahramani ...
  • 19. Kashyap BK, Singh VV, Solanki MK, Kumar A, Ruokolainen ...
  • 20. Makvandi P, Josic U, Delfi M, Pinelli F, Jahed ...
  • 21. Vyas K, Rathod M, Patel MM. Insight on nano ...
  • 22. Fernandez-Fernandez A, Manchanda R, Kumari M. Lipid-engineered nanotherapeutics for ...
  • 23. Waheed S, Li Z, Zhang F, Chiarini A, Armato ...
  • 24. Mazidi Z, Javanmardi S, Naghib SM, Mohammadpour Z. Smart ...
  • 25. De R, Mahata MK, Kim KT. Structure‐based varieties of ...
  • 26. Yang T, Zhai J, Hu D, Yang R, Wang ...
  • 27. Sharma H, Mondal S. Functionalized Graphene Oxide for Chemotherapeutic ...
  • 28. Aydinlioglu E. pH-responsive polypeptide-based self-assemblies as drug and gene ...
  • 29. Ghasemii K, Darroudi M, Rahimmanesh I, Ghomi M, Hassanpour ...
  • 30. Mikušová V, Mikuš P. Advances in chitosan-based nanoparticles for ...
  • 31. Wang SY, Hu HZ, Qing XC, Zhang ZC, Shao ...
  • 32. Jash A, Ubeyitogullari A, Rizvi SS. Liposomes for oral ...
  • 33. Kunjiappan S, Pavadai P, Vellaichamy S, Ram Kumar Pandian ...
  • 34. Kemp JA, Kwon YJ. Cancer nanotechnology: current status and ...
  • 35. Sultana A, Zare M, Thomas V, Kumar TS, Ramakrishna ...
  • 36. Tomalia DA. Dendrimers, Dendrons, and the Dendritic State: Reflection ...
  • 37. Filipczak N, Yalamarty SSK, Li X, Parveen F, Torchilin ...
  • 38. Shabatina TI, Vernaya OI, Shimanovskiy NL, Melnikov MY. Metal ...
  • Sliver Nanoparticles: A Promising Strategy in Preventive Dentistry [مقاله ژورنالی]
  • 40. Faid AH, Shouman SA, Badr YA, Sharaky M. Enhanced ...
  • 41. Gote V, Nookala AR, Bolla PK, Pal D. Drug ...
  • 42. Huang D, Sun L, Huang L, Chen Y. Nanodrug ...
  • 43. Wang X, Zhang H, Chen X, Wu C, Ding ...
  • 44. Subhan MA, Yalamarty SSK, Filipczak N, Parveen F, Torchilin ...
  • 45. Sabir F, Qindeel M, Zeeshan M, Ul Ain Q, ...
  • 46. Aflori M. Smart nanomaterials for biomedical applications—a review. Nanomaterials. ...
  • 47. Saberian E, Jenča A, Petrášová A, Zare-Zardini H, Ebrahimifar ...
  • 48. Bhalani DV, Nutan B, Kumar A, Singh Chandel AK. ...
  • 49. Sartaj A, Qamar Z, Qizilbash FF, Annu, Md S, ...
  • 50. Rauf A, Abu-Izneid T, Khalil AA, Imran M, Shah ...
  • 51. Kumbhar PR, Kumar P, Lasure A, Velayutham R, Mandal ...
  • 52. Afrin H, Geetha Bai R, Kumar R, Ahmad SS, ...
  • 53. Sanati M, Figueroa-Espada CG, Han EL, Mitchell MJ, Yavari ...
  • 54. Su S, M. Kang P. Recent Advances in Nanocarrier-Assisted ...
  • 55. Ketabat F, Pundir M, Mohabatpour F, Lobanova L, Koutsopoulos ...
  • 56. Kalaydina R-V, Komal B, Bessi Q, Alexandria D, and ...
  • 57. Pi C, Wenmei Z, Mingtang Z, Jiyuan Y, Hongping ...
  • 58. de Lima JM, Bonan PR, da Cruz Perez DE, ...
  • 59. Jo SD, Ku SH, Won YY, Kim SH, Kwon ...
  • 60. Umapathy VR, Natarajan PM, Swamikannu B. Review of the ...
  • 61. Nabavizadeh MR, Moazzami F, Gholami A, Mehrabi V, Ghahramani ...
  • 62. Abbaszadegan A, Ghahramani Y, Farshad M, Sedigh-Shams M, Gholami ...
  • 63. Noga M, Milan J, Frydrych A, Jurowski K. Toxicological ...
  • 64. Alshawwa SZ, Kassem AA, Farid RM, Mostafa SK, Labib ...
  • 65. Bhatia SN, Chen X, Dobrovolskaia MA, Lammers T. Cancer ...
  • 66. Deshmukh R, Sethi P, Singh B, Shiekmydeen J, Salave ...
  • 67. Hassan SA-DH, Almaliki MNS, Hussein ZA, Albehadili HM, Rabeea ...
  • 68. Petrovic S, Bita B, Barbinta-Patrascu M-E. Nanoformulations in Pharmaceutical ...
  • 69. Khaksar E, Asadi A, Rezaei M, Abbasi F, Ghahramani ...
  • 70. Asadi A, Khaksar E, Valanik S, Ghahramani Y. New ...
  • 71. Asadi A, Khaksar E, Hosseinpoor S, Abbasi R, Ghahramani ...
  • نمایش کامل مراجع